The Unites States Supreme Court. Image Credit: Wikimedia
A St. Louis gardener's cancer diagnosis after decades of Roundup exposure now heads to the U.S. Supreme Court, where Bayer seeks to slam the door on tens of thousands of similar claims by arguing federal approval trumps state-level accountability for failure to warn.
On January 16, 2026, the Supreme Court granted certiorari in Monsanto Company v. John L. Durnell, limited to whether the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) preempts state-law failure-to-warn claims when the EPA has not required a cancer warning on the label. John Durnell, diagnosed with non-Hodgkin lymphoma in 2019 after long-term use of Roundup, won a $1.25 million jury verdict in Missouri state court for the company's failure to warn of risks. Lower courts upheld it, but Bayer appealed, insisting EPA approval of the label without a cancer warning blocks such suits nationwide.
Federal Preemption as Corporate Shield
Bayer, which acquired Monsanto in 2018, has paid over $10 billion settling prior Roundup claims and faces more than 60,000 pending lawsuits. The company argues FIFRA's uniformity provision prevents states from imposing labeling requirements "in addition to or different from" federal ones. If the Court rules for Bayer, juries could no longer hold pesticide makers liable for omitting warnings the EPA did not mandate—even if internal knowledge or emerging science suggested danger.
Plaintiff attorneys counter that Bayer never sought EPA approval for a cancer warning despite awareness of risks. Michael Baum, who litigated major Roundup cases, warned a favorable ruling would create "blanket immunity for over 57,000 pesticides regulated under federal law."
R. Brent Wisner, representing plaintiffs, described the outcome Bayer seeks as elevating pesticide manufacturers to "a special class of corporations" immune from standard tort accountability.
Trump Administration Reverses Course to Back Bayer
The Trump administration filed an amicus brief urging the Court to take the case and rule that FIFRA preempts state claims. Solicitor General D. John Sauer argued EPA's repeated findings that glyphosate is "not likely to be carcinogenic to humans" and its approval of Roundup labels without cancer warnings mean states cannot second-guess via liability. This reversed the prior administration's stance, which had argued against broad preemption.
MAHA advocates and health groups condemned the shift as favoring corporate interests over public health, especially amid the push for human revival and reduced chemical burdens.
Glyphosate Evidence Under Fire
Bayer insists glyphosate poses no cancer risk, citing EPA conclusions. Yet independent assessments conflict sharply. The World Health Organization's International Agency for Research on Cancer classified glyphosate as "probably carcinogenic" in 2015.
In November 2025, Regulatory Toxicology and Pharmacology retracted a 2000 paper long relied on by regulators to affirm glyphosate safety. The retraction cited serious ethical concerns, including Monsanto employees secretly contributing to or writing parts of the article without disclosure, and the paper's failure to address multiple long-term studies showing potential toxicity.
Such ghostwriting revelations undermine trust in the regulatory process that Bayer now invokes for preemption.
Industry's Parallel Legislative Push Falters
Bayer and allies lobbied for legislative shields matching the sought-after court ruling. A provision in a 2026 appropriations bill would have barred federal funds for policies or labeling inconsistent with EPA assessments, effectively blocking state warnings based on new evidence. Bipartisan opposition, led by Rep. Chellie Pingree, stripped the language before passage.
Industry groups like the Modern Ag Alliance advanced state-level liability shields in Georgia and North Dakota, declaring EPA oversight supreme. Efforts continue in the pending Farm Bill, with House Agriculture Committee Chair Glenn Thompson prioritizing protections for pesticide companies.
Human Stakes in Regulatory Capture
For everyday users—gardeners, farmworkers, families—the case exposes how federal deference can nullify state protections against known hazards. A pro-Bayer ruling would insulate an industry from consequences even as science questions old approvals and retracts tainted studies. It reinforces surveillance-like regulatory capture where agencies, influenced by industry, limit citizen recourse under the Fourth Amendment spirit of individual security against unchecked corporate power.
Oral arguments await; a decision could arrive by June 2026.
